Preventing Epilepsy Through Antiseizure Medication in Tuberous Sclerosis Complex: Gabrielle Rushing, PhD
The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
“There's been some research and some trials showing that the earlier the seizure control, the better the developmental outcomes for those individuals. So really, seizure control was top priority.”
Clinical trials such as the Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex (PREVeNT) trial (NCT02849457) are continuing to advance research for controlling seizures in patients with tuberous sclerosis complex (TSC). The trial evaluates whether the use of vigabatrin in infants with TSC will have a positive impact at 24 months of age on the patients’ developmental outcomes and quality of life.
Gabrielle Rushing, PhD, had an abstract presented at the 2022 American Epilepsy Society Annual Meeting, held December 2 to 6, in Nashville, Tennessee, based on results from a whole genome sequencing pilot study conducted by the TSC Alliance. She mentioned in her presentation that there are opportunities for research to explore genetic testing for TSC as a form of preventive care.
Rushing, director of research at the TSC Alliance, sat down with NeurologyLive® in an interview at the meeting and offered an overview about the current knowns and unknowns with preventing seizures in TSC, with trials such as PREVeNT leading the way. She also provided her clinical perspective on the most important aspect of care for patients with the condition along with some of the most recent advancements.
